Bisphosphonate therapy for osteogenesis imperfecta

K Dwan, CA Phillipi, RD Steiner… - Cochrane database of …, 2016 - cochranelibrary.com
Background Osteogenesis imperfecta is caused by a genetic defect resulting in an abnormal
type I collagen bone matrix which typically results in multiple fractures with little or no …

Juvenile idiopathic arthritis

A Ravelli, A Martini - The Lancet, 2007 - thelancet.com
Juvenile idiopathic arthritis is a broad term that describes a clinically heterogeneous group
of arthritides of unknown cause, which begin before 16 years of age. This term …

The IOC consensus statement: beyond the female athlete triad—relative energy deficiency in sport (RED-S)

M Mountjoy, J Sundgot-Borgen, L Burke… - British journal of sports …, 2014 - bjsm.bmj.com
Protecting the health of the athlete is a goal of the International Olympic Committee (IOC).
The IOC convened an expert panel to update the 2005 IOC Consensus Statement on the …

2014 female athlete triad coalition consensus statement on treatment and return to play of the female athlete triad: 1st International Conference held in San Francisco …

MJ De Souza, A Nattiv, E Joy, M Misra… - British journal of sports …, 2014 - bjsm.bmj.com
The Female Athlete Triad is a medical condition often observed in physically active girls and
women, and involves three components:(1) low energy availability with or without …

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper

CA Migliorati, J Casiglia, J Epstein, PL Jacobsen… - The Journal of the …, 2005 - Elsevier
Background This position paper addresses the prevention of bisphosphonate-associated
osteonecrosis (BON) and the management of care of patients with cancer and/or …

Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

CA Migliorati, MM Schubert, DE Peterson, LM Seneda - Cancer, 2005 - Wiley Online Library
BACKGROUND The current report presented 17 patients with cancer with bone metastases
and 1 patient with osteopenia who received treatment with bisphosphonates and who …

Glucocorticoid-induced osteoporosis: who to treat with what agent?

R Rizzoli, E Biver - Nature Reviews Rheumatology, 2015 - nature.com
Among the adverse events of glucocorticoid treatment are bone loss and fractures. Despite
available, effective preventive measures, many patients receiving or initiating glucocorticoid …

Clinical review: bisphosphonate use in childhood osteoporosis

LK Bachrach, LM Ward - The Journal of Clinical Endocrinology & …, 2009 - academic.oup.com
Context: As awareness of osteoporosis in childhood has increased, so have pressures to
consider use of the pharmacological agents used to treat osteoporosis in adults. This review …

Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study

D Gatti, F Antoniazzi, R Prizzi, V Braga… - Journal of Bone and …, 2005 - academic.oup.com
In a randomized controlled study, we investigated the effect of treatment with intravenous
neridronate in prepubertal children with OI. Our study suggests that quarterly intravenous …

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement

AD Letocha, HL Cintas, JF Troendle… - Journal of Bone and …, 2005 - academic.oup.com
Bisphosphonates have been widely administered to children with OI based on observational
trials. A randomized controlled trial of q3m intravenous pamidronate in children with types III …